These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 30844945)

  • 21. Progress in the understanding and utilization of biologic response modifiers in the treatment of uveitis.
    Maleki A; Meese H; Sahawneh H; Foster CS
    Expert Rev Clin Immunol; 2016 Jul; 12(7):775-86. PubMed ID: 26972783
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative efficacy between adalimumab and infliximab in the treatment of non-infectious intermediate uveitis, posterior uveitis, and panuveitis: a retrospective observational study of 107 patients.
    Fabiani C; Vitale A; Rigante D; Emmi G; Bitossi A; Lopalco G; Sota J; Guerriero S; Orlando I; Gentileschi S; Iannone F; Frediani B; Galeazzi M; Vannozzi L; Tosi GM; Cantarini L
    Clin Rheumatol; 2019 Feb; 38(2):407-415. PubMed ID: 30099655
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Update on the systemic management of noninfectious uveitis in children and adolescents.
    Leal I; Steeples LR; Wong SW; Giuffrè C; Pockar S; Sharma V; Green EKY; Payne J; Jones NP; Chieng ASE; Ashworth J
    Surv Ophthalmol; 2024; 69(1):103-121. PubMed ID: 36682467
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-Tumor Necrosis Factor α versus Tocilizumab in the Treatment of Refractory Uveitic Macular Edema: A Multicenter Study from the French Uveitis Network.
    Leclercq M; Andrillon A; Maalouf G; Sève P; Bielefeld P; Gueudry J; Sené T; Moulinet T; Rouvière B; Sène D; Desbois AC; Domont F; Touhami S; El Chamieh C; Cacoub P; Bodaghi B; Biard L; Saadoun D
    Ophthalmology; 2022 May; 129(5):520-529. PubMed ID: 34793830
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Profile of adalimumab and its potential in the treatment of uveitis.
    Balevic SJ; Rabinovich CE
    Drug Des Devel Ther; 2016; 10():2997-3003. PubMed ID: 27698552
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rise of biologics in noninfectious uveitis: a retrospective cohort study from Nepal.
    Sharma S; Kharel R; Parajuli S; Jha S
    Ann Med Surg (Lond); 2023 May; 85(5):1486-1489. PubMed ID: 37229040
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparing biologic options for the management of Behcet's disease-related uveitis.
    Vitale A; Caggiano V; Berlengiero V; Perfetti MO; Sota J; Tosi GM; Frediani B; Cantarini L; Fabiani C
    Expert Rev Clin Immunol; 2023 Mar; 19(3):315-328. PubMed ID: 36715297
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adalimumab in the treatment of non-infectious uveitis.
    Burek-Michalska A; Turno-Kręcicka A
    Adv Clin Exp Med; 2020 Oct; 29(10):1231-1236. PubMed ID: 33125196
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New observations and emerging ideas in diagnosis and management of non-infectious uveitis: A review.
    Rosenbaum JT; Bodaghi B; Couto C; Zierhut M; Acharya N; Pavesio C; Tay-Kearney ML; Neri P; Douglas K; Pathai S; Song AP; Kron M; Foster CS
    Semin Arthritis Rheum; 2019 Dec; 49(3):438-445. PubMed ID: 31301816
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Occurrence of adverse events in patients with JIA receiving biologic agents: long-term follow-up in a real-life setting.
    Tarkiainen M; Tynjälä P; Vähäsalo P; Lahdenne P
    Rheumatology (Oxford); 2015 Jul; 54(7):1170-6. PubMed ID: 25504896
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biological and Therapeutic Role of Interleukin-6 in Non-Infectious Uveitis: A Narrative Review.
    Cifuentes-González C; Mejía-Salgado G; Rojas-Carabali W; Diez-Bahamón LA; Garzón-Dangond JM; Janela B; de-la-Torre A; Agrawal R
    Ocul Immunol Inflamm; 2024 Oct; ():1-15. PubMed ID: 39404707
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The use of biologic agents in the management of uveitis.
    Trivedi A; Katelaris C
    Intern Med J; 2019 Nov; 49(11):1352-1363. PubMed ID: 30582273
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Biologics in uveitis].
    Feurer E; Bielefeld P; Saadoun D; Sève P
    Rev Med Interne; 2015 Feb; 36(2):107-16. PubMed ID: 25239400
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Indications and effects of biological agents in the treatment of noninfectious uveitis.
    Li B; Yang L; Bai F; Tong B; Liu X
    Immunotherapy; 2022 Aug; 14(12):985-994. PubMed ID: 35695019
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Medical Therapy of Uveitic Macular Edema: Biologic Agents.
    Radosavljevic A; Agarwal M; Bodaghi B; Smith JR; Zierhut M
    Ocul Immunol Inflamm; 2020 Nov; 28(8):1239-1250. PubMed ID: 32058830
    [No Abstract]   [Full Text] [Related]  

  • 36. Anti-Interleukin-6 Receptor Tocilizumab for Severe Juvenile Idiopathic Arthritis-Associated Uveitis Refractory to Anti-Tumor Necrosis Factor Therapy: A Multicenter Study of Twenty-Five Patients.
    Calvo-Río V; Santos-Gómez M; Calvo I; González-Fernández MI; López-Montesinos B; Mesquida M; Adán A; Hernández MV; Maíz O; Atanes A; Bravo B; Modesto C; Díaz-Cordovés G; Palmou-Fontana N; Loricera J; González-Vela MC; Demetrio-Pablo R; Hernández JL; González-Gay MA; Blanco R
    Arthritis Rheumatol; 2017 Mar; 69(3):668-675. PubMed ID: 27696756
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Janus Kinase Inhibitors as a Third-Line Therapy for Refractory Endogenous Noninfectious Uveitis.
    Garweg JG; Straessle KA
    Ocul Immunol Inflamm; 2024 May; ():1-8. PubMed ID: 38709218
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and Safety of Adalimumab and Infliximab for Noninfectious Uveitis.
    Tai F; Mehraban Far P; Pechlivanoglou P; Ramsay LC; Georgakopoulos JR; Sander B; Derzko-Dzulynsky LA; Felfeli T
    Ophthalmology; 2022 Mar; 129(3):357-359. PubMed ID: 34634363
    [No Abstract]   [Full Text] [Related]  

  • 39. Primary (Month-6) Outcomes of the STOP-Uveitis Study: Evaluating the Safety, Tolerability, and Efficacy of Tocilizumab in Patients With Noninfectious Uveitis.
    Sepah YJ; Sadiq MA; Chu DS; Dacey M; Gallemore R; Dayani P; Hanout M; Hassan M; Afridi R; Agarwal A; Halim MS; Do DV; Nguyen QD
    Am J Ophthalmol; 2017 Nov; 183():71-80. PubMed ID: 28887113
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Infliximab Versus Adalimumab in the Treatment of Refractory Inflammatory Uveitis: A Multicenter Study From the French Uveitis Network.
    Vallet H; Seve P; Biard L; Baptiste Fraison J; Bielefeld P; Perard L; Bienvenu B; Abad S; Rigolet A; Deroux A; Sene D; Perlat A; Marie I; Feurer E; Hachulla E; Fain O; Clavel G; Riviere S; Bouche PA; Gueudry J; Pugnet G; Le Hoang P; Resche Rigon M; Cacoub P; Bodaghi B; Saadoun D;
    Arthritis Rheumatol; 2016 Jun; 68(6):1522-30. PubMed ID: 27015607
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.